source
- Experimental drugs to lower Lp(a) move toward market, promising billions in potential salesHigh levels of lipoprotein(a), or Lp(a), are a genetic risk factor for heart disease that affects roughly one in five people and currently has no approved therapy. Several drugmakers are moving ex…
- Hansoh says China’s biopharma is shifting from follower to frontrunner, now behind 30% of investigational drugsHansoh Pharmaceutical used its first‑half earnings release to claim that China’s innovative biopharma sector is moving from a follower role to a frontrunner position. The company highlighted that…